1. Home
  2. LEXX vs WVVI Comparison

LEXX vs WVVI Comparison

Compare LEXX & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • WVVI
  • Stock Information
  • Founded
  • LEXX 2004
  • WVVI 1983
  • Country
  • LEXX Canada
  • WVVI United States
  • Employees
  • LEXX N/A
  • WVVI N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • WVVI Beverages (Production/Distribution)
  • Sector
  • LEXX Health Care
  • WVVI Consumer Staples
  • Exchange
  • LEXX Nasdaq
  • WVVI Nasdaq
  • Market Cap
  • LEXX 22.7M
  • WVVI 20.4M
  • IPO Year
  • LEXX N/A
  • WVVI N/A
  • Fundamental
  • Price
  • LEXX $1.06
  • WVVI $2.93
  • Analyst Decision
  • LEXX Strong Buy
  • WVVI
  • Analyst Count
  • LEXX 1
  • WVVI 0
  • Target Price
  • LEXX $4.00
  • WVVI N/A
  • AVG Volume (30 Days)
  • LEXX 283.7K
  • WVVI 15.6K
  • Earning Date
  • LEXX 11-25-2025
  • WVVI 11-13-2025
  • Dividend Yield
  • LEXX N/A
  • WVVI N/A
  • EPS Growth
  • LEXX N/A
  • WVVI N/A
  • EPS
  • LEXX N/A
  • WVVI N/A
  • Revenue
  • LEXX $615,923.00
  • WVVI $38,384,350.00
  • Revenue This Year
  • LEXX $46.98
  • WVVI N/A
  • Revenue Next Year
  • LEXX $17.26
  • WVVI N/A
  • P/E Ratio
  • LEXX N/A
  • WVVI N/A
  • Revenue Growth
  • LEXX 49.85
  • WVVI N/A
  • 52 Week Low
  • LEXX $0.77
  • WVVI $2.49
  • 52 Week High
  • LEXX $2.85
  • WVVI $7.18
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 56.87
  • WVVI 33.24
  • Support Level
  • LEXX $0.99
  • WVVI $2.75
  • Resistance Level
  • LEXX $1.21
  • WVVI $3.84
  • Average True Range (ATR)
  • LEXX 0.08
  • WVVI 0.28
  • MACD
  • LEXX 0.02
  • WVVI -0.07
  • Stochastic Oscillator
  • LEXX 58.97
  • WVVI 29.41

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About WVVI Willamette Valley Vineyards Inc.

Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.

Share on Social Networks: